The Combination of Schisandrol B and Wedelolactone Synergistically Reverses Hepatic Fibrosis Via Modulating Multiple Signaling Pathways in Mice

The Combination of Schisandrol B and Wedelolactone Synergistically Reverses Hepatic Fibrosis Via Modulating Multiple Signaling Pathways in Mice

Hepatic fibrosis represents an important event in the progression of chronic liver injury to cirrhosis, and is characterized by excessive extracellular matrix proteins aggregation. Early fibrosis can be reversed by inhibiting hepatocyte injury, inflammation, or hepatic stellate cells activation, so...

Full description

Bibliographic Details
Main Authors: Yongqiang Ai, Wei Shi, Xiaobin Zuo, Xiaoming Sun, Yuanyuan Chen, Zhilei Wang, Ruisheng Li, Xueai Song, Wenzhang Dai, Wenqing Mu, Kaixin Ding, Zhiyong Li, Qiang Li, Xiaohe Xiao, Xiaoyan Zhan, Zhaofang Bai
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Pharmacology
Subjects:
schisandrol B
wedelolactone
hepatic fibrosis
combined pharmacotherapy
TGF-β1/smads signaling pathway
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.655531/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.655531/full

Similar Items